ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Insider Sells $15,234.96 in Stock

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) insider James Kihara sold 1,028 shares of the firm’s stock in a transaction dated Tuesday, April 8th. The shares were sold at an average price of $14.82, for a total transaction of $15,234.96. Following the completion of the transaction, the insider now directly owns 22,257 shares in the company, valued at $329,848.74. This trade represents a 4.41 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

James Kihara also recently made the following trade(s):

• On Wednesday, March 26th, James Kihara sold 1,095 shares of ACADIA Pharmaceuticals stock. The shares were sold at an average price of $17.05, for a total transaction of $18,669.75.
• On Monday, February 24th, James Kihara sold 475 shares of ACADIA Pharmaceuticals stock. The stock was sold at an average price of $19.96, for a total transaction of $9,481.00.

ACADIA Pharmaceuticals Stock Performance

NASDAQ ACAD traded down $0.51 during trading on Tuesday, hitting $14.10. The stock had a trading volume of 1,982,762 shares, compared to its average volume of 1,841,010. ACADIA Pharmaceuticals Inc. has a 12 month low of $13.89 and a 12 month high of $20.68. The company’s 50-day moving average price is $17.89 and its two-hundred day moving average price is $17.00. The company has a market capitalization of $2.35 billion, a PE ratio of 18.08 and a beta of 0.54.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Guggenheim lowered ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $23.00 to $20.00 in a research report on Friday, January 3rd. Morgan Stanley restated an “equal weight” rating and set a $20.00 target price on shares of ACADIA Pharmaceuticals in a report on Friday, March 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $28.00 price target on shares of ACADIA Pharmaceuticals in a research note on Thursday, February 27th. HC Wainwright reiterated a “buy” rating and issued a $27.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Finally, Needham & Company LLC restated a “buy” rating and set a $28.00 price objective on shares of ACADIA Pharmaceuticals in a report on Tuesday. Eight equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $23.93.

Institutional Trading of ACADIA Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its stake in ACADIA Pharmaceuticals by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 13,947,640 shares of the biopharmaceutical company’s stock valued at $255,939,000 after buying an additional 104,444 shares during the last quarter. State Street Corp increased its position in shares of ACADIA Pharmaceuticals by 3.0% in the third quarter. State Street Corp now owns 5,973,874 shares of the biopharmaceutical company’s stock valued at $91,878,000 after acquiring an additional 173,084 shares during the last quarter. Geode Capital Management LLC raised its holdings in ACADIA Pharmaceuticals by 1.1% during the third quarter. Geode Capital Management LLC now owns 2,875,540 shares of the biopharmaceutical company’s stock worth $44,234,000 after acquiring an additional 30,826 shares in the last quarter. First Trust Advisors LP boosted its position in ACADIA Pharmaceuticals by 27.0% during the fourth quarter. First Trust Advisors LP now owns 2,700,125 shares of the biopharmaceutical company’s stock valued at $49,547,000 after purchasing an additional 574,251 shares during the last quarter. Finally, SG Americas Securities LLC grew its stake in ACADIA Pharmaceuticals by 380.3% in the fourth quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company’s stock valued at $45,576,000 after purchasing an additional 1,966,607 shares in the last quarter. Institutional investors own 96.71% of the company’s stock.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.